Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure
Cells · 20.03.2025 · 14 (6) · 460
DOI: 10.3390/cells14060460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.03.2025. Verfasst von Ivan Sherstnev und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12…. Hauptthemen laut MEDLINE: Heart Failure, Myocytes, Cardiac, Cyclic Nucleotide Phosphodiesterases, Type 4. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Fondation Leducq, Italian Ministry of Health.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Phosphodiesterase 4 (PDE4) is a key regulator of cyclic adenosine monophosphate (cAMP) signalling in cardiomyocytes, controlling contractility, calcium handling, and hypertrophic responses. PDE4 provides spatial and temporal precision to cAMP signalling, particularly under β-adrenergic stimulation, through its compartmentalised activity in subcellular nanodomains, including the sarcoplasmic reticulum, plasma membrane and nuclear envelope. This review highlights the cardiac PDE4 isoforms PDE4A, PDE4B and PDE4D, focusing on their distinct localisation and contributions to cardiac physiology and pathophysiology, particularly in heart failure and arrhythmias. Although PDE4 plays a smaller role in overall cAMP hydrolysis in human hearts than in rodents, its compartmentalised function remains critical. Recent therapeutic advances have shifted from pan-PDE4 inhibitors to isoform-specific approaches to enhance efficacy while minimising systemic toxicity. We discuss the potential of selective PDE4 modulators, gene therapies and combination strategies in restoring cAMP compartmentation and preventing maladaptive cardiac remodelling. By integrating rodent and human studies, this review underscores the translational challenges and therapeutic opportunities surrounding PDE4, positioning it as both a key regulator of cardiac signalling and a promising target for heart failure therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK.
- Department of Surgery, Dentistry, Pediatrics and Gynecology, Division of Cardiac Surgery, University of Verona, 37126 Verona, Italy.
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, 10126 Torino, Italy.
ORCID-Profile: Giovanni Battista Luciani, Alessandra Ghigo, Emilio Hirsch, Julia Gorelik
Förderung
- British Heart Foundation
- Fondation Leducq
- Italian Ministry of Health
- Italian Ministry of Education, Universities and Research
- Leducq Foundation for Cardiovascular Research
Zitieren
APA
Sherstnev, I., Judina, A., Luciani, G. B., Ghigo, A., Hirsch, E., & Gorelik, J. (2025). Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure. Cells, 14(6), 460. https://doi.org/10.3390/cells14060460
Vancouver
Sherstnev I, Judina A, Luciani GB, Ghigo A, Hirsch E, Gorelik J. Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure. Cells. 2025;14(6):460. doi:10.3390/cells14060460
BibTeX
@article{Sherstnev2025,
author = {Sherstnev, Ivan and Judina, Aleksandra and Luciani, Giovanni Battista and Ghigo, Alessandra and Hirsch, Emilio and Gorelik, Julia},
title = {Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure},
journal = {Cells},
year = {2025},
volume = {14},
number = {6},
pages = {460},
doi = {10.3390/cells14060460}
}
EUVIMED